⌘K
Loading ticker…
As of 2026-08-24, SAB Biotherapeutics, Inc. Common Stock (SABS) has a 3-month relative strength percentile of 34 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 52. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 4.3%, relative volume 1.55×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
SABS appears in 1 ETF as of May 2026: AVSC at 0.01% weight, $244K notional.
Held by 4 ETFs · $10M across latest filings · largest weight 1.03% (SURI).
Top 1 by value, from SEC N-PORT-P filings dated May 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| AVSC | 0.01% | $244K | — |
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
News
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | SABS Jan avg: -5.61% median: 1.22% win: 50% σ: 28.02% n: 4 2022-04-12 → 2026-07-31 | SABS Feb avg: -14.63% median: -14.26% win: 0% σ: 10.73% n: 4 2022-04-12 → 2026-07-31 | SABS Mar avg: -14.39% median: -13.53% win: 25% σ: 15.06% n: 4 2022-04-12 → 2026-07-31 | SABS Apr avg: 23.27% median: -2.35% win: 40% σ: 46.98% n: 5 2022-04-12 → 2026-07-31 | SABS May avg: -10.24% median: -3.74% win: 20% σ: 20.12% n: 5 2022-04-12 → 2026-07-31 | SABS Jun avg: -3.21% median: -6.74% win: 40% σ: 16.78% n: 5 2022-04-12 → 2026-07-31 | SABS Jul avg: -7.95% median: -8.46% win: 20% σ: 11.97% n: 5 2022-04-12 → 2026-07-31 | SABS Aug avg: -7.43% median: -2.59% win: 50% σ: 20.72% n: 4 2022-04-12 → 2026-07-31 (current) | SABS Sep avg: -5.97% median: -5.76% win: 25% σ: 5.52% n: 4 2022-04-12 → 2026-07-31 | SABS Oct avg: 42.38% median: 43.55% win: 100% σ: 20.85% n: 4 2022-04-12 → 2026-07-31 | SABS Nov avg: 7.08% median: 8.61% win: 50% σ: 16.12% n: 4 2022-04-12 → 2026-07-31 | SABS Dec avg: -12.51% median: -17.29% win: 25% σ: 32.74% n: 4 2022-04-12 → 2026-07-31 |